SCHEMBL1780689

SCHEMBL1780689

Cn1nc(N2CCC(Oc3ccccc3)C2)c(=O)n(C)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 1/20 0.47
▸ GBA1 P04062 1/20 0.44
▸ FPR2 P25090 1/20 0.44
▸ PROKR1 Q8TCW9 1/20 0.44
▸ FFAR4 Q5NUL3 3/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.42
▸ ACACB O00763 1/20 0.42
▸ PDE3B Q13370 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ PDE10A Q9Y233 1/20 0.41
▸ OXTR P30559 1/20 0.41
▸ AVPR1A P37288 1/20 0.41
▸ CARM1 Q86X55 1/20 0.40
▸ PRMT6 Q96LA8 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ CTSV O60911 1/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1782040 0.81 FPR2 (0.49) NR3C1FPR2PROKR1HRH3CHRM4
SCHEMBL1782398 0.81 SCD (0.59) PDE10A
SCHEMBL1782603 0.79 FPR2 (0.52) FPR2PROKR1
SCHEMBL1784138 0.77 SCD (0.50) FPR2PROKR1HRH3PDE3BPDE3A
SCHEMBL1783508 0.77 SCD (0.64) PDE10AOXTRAVPR1A
SCHEMBL1781805 0.76 SCD (0.49) FPR2PROKR1
SCHEMBL1782817 0.76 SCD (0.67) PDE10A
SCHEMBL1779895 0.73 SCD (0.67) —
SCHEMBL1781459 0.72 SMN1; SMN2 (0.55) NR3C1CARM1PRMT6SMN1; SMN2
SCHEMBL10262302 0.71 SMN1; SMN2 (0.59) HRH3CARM1PRMT6SMN1; SMN2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328886-B1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PF MEDICAMENT (FR) 2016-12-28 — — EP disclosed
US-8618287-B2 Derivatives of triazines and uracils, their preparation and their application in human therapeutics PIERRE FABRE MEDICAMENT (FR) 2013-12-31 — — US disclosed
EP-2328886-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS Pierre Fabre Médicament (FR) 2011-06-08 — — EP disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
WO-2010006962-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2010-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS UNG, TYMS, UMPS NR3C1 829/4885GBA1 855/4885FPR2 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback